证券代码：002626 证券简称：金达威 公告编号：2025-041 厦门金达威集团股份有限公司 第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）第九届董事会第一次会 议于 2025 年 5 月 15 日在厦门市海沧区公司五层会议室以现场结合通讯表决的方 式召开。经全体董事一致同意，豁免本次董事会提前通知期限。本次会议由全体 董事一致推举江斌先生主持，公司董事会成员应到九人，实际参加表决人数九人。 公司副总经理、财务总监等高级管理人员候选人亦列席了本次会议。本次会议的 召集、召开符合《中华人民共和国公司法》和公司章程的有关规定。 经与会董事认真审议，本次会议以现场结合通讯表决的方式审议通过了以下 议案： 一、 会议以 9 票同意、0 票反对、0 票弃权的表决结果审议通过《关于选举 第九届董事会董事长、副董事长的议案》 选举江斌先生为公司第九届董事会董事长、顾卫华先生为第九届董事会副董 事长，任期自本次会议审议通过之日起至第九届董事会届满之日止。 具体内容详见公司于同日在巨潮资讯网（w ...

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Core Viewpoint - The NMN concept sector has shown a significant increase of 2.07%, leading among various concept sectors, with notable stocks like Xiwang Food and Jindawei reaching their daily limit up [1][2]. Group 1: Sector Performance - The NMN concept sector ranked first in daily gains, with 21 stocks rising, including Xiwang Food and Jindawei, which hit the daily limit up [1]. - Other sectors with positive performance include synthetic biology (2.05%), pet economy (1.98%), and dairy industry (1.67%) [2]. - The sectors with the largest declines include Huawei Pangu (-3.76%) and DRG/DIP (-3.30%) [2]. Group 2: Capital Flow - The NMN concept sector experienced a net inflow of 436 million yuan, with 17 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow [2]. - Jindawei led the net inflow with 155.31 million yuan, followed by Xiwang Food (99.59 million yuan) and Zhejiang Medicine (50.07 million yuan) [2][3]. - The net inflow ratios for Jindawei, Xiwang Food, and Zhejiang Medicine were 29.36%, 27.57%, and 15.18%, respectively [3]. Group 3: Individual Stock Performance - Jindawei saw a daily increase of 9.99% with a turnover rate of 4.82% and a net inflow of 155.31 million yuan [3]. - Xiwang Food increased by 10.07% with a turnover rate of 10.94% and a net inflow of 99.59 million yuan [3]. - Other notable performers include Yabenn Chemical (4.96% increase) and Yikang Pharmaceutical (3.02% increase) [3].

Group 1 - The vitamin concept sector rose by 1.55%, ranking 6th among concept sectors, with 48 stocks increasing in value, including Meino Biological reaching a 20% limit up [1][2] - Notable gainers in the vitamin sector included Xiwang Food, Yong'an Pharmaceutical, and Jindawei, which all hit the limit up, while Xianle Health, Oukang Pharmaceutical, and Fujilai also saw significant increases of 13.41%, 8.31%, and 6.54% respectively [1][2] - The sector experienced a net inflow of 548 million yuan from main funds, with 41 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow, led by Jindawei with 155 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jindawei, Xiwang Food, and Andisu, with net inflow ratios of 29.36%, 27.57%, and 20.19% respectively [3][4] - The trading volume and turnover rates for leading stocks in the vitamin sector were significant, with Jindawei showing a turnover rate of 4.82% and a price increase of 9.99% [3][4] - Other notable stocks included Yong'an Pharmaceutical with a 9.99% increase and a turnover rate of 31.54%, and Zhejiang Pharmaceutical with a modest increase of 0.29% [3][4]

Group 1 - The core viewpoint of the article highlights the strong performance of the consumer sector, particularly in new consumption areas such as daily chemicals, health products, and pet economy, leading to significant stock price increases for companies like Huaye Spice and Baiyang Co. [1] - The article notes that several companies, including Jindawei, Xiwang Food, and Jiaoda Onl, have also seen their stock prices hit the daily limit, indicating a broad market trend in the consumer sector [1] - Institutions have pointed out that domestic new consumption enterprises are experiencing robust growth, driven by ongoing upgrades in aesthetics and spiritual satisfaction, particularly in emotional and experiential consumption [1]

Market Overview - On May 15, A-shares experienced a decline, with the Shanghai Composite Index falling by 0.42% to 3389.75 points, the Shenzhen Component Index down by 1.12%, and the ChiNext Index decreasing by 1.35% [1][2] - The total trading volume for A-shares reached 765.59 billion yuan [1] Economic Indicators - The People's Bank of China conducted a 645 billion yuan reverse repurchase operation with a fixed interest rate of 1.40%, resulting in a net withdrawal of 219.1 billion yuan for the day [2] Industry Insights - The China-U.S. Economic and Trade Cooperation Exchange Conference was successfully held in Washington, emphasizing the long-standing and mutually beneficial trade relationship between the two countries [3] - Despite current challenges, there is significant potential for future cooperation, particularly in maintaining global supply chain stability [3] Sector Performance - Port and shipping stocks saw a resurgence, with notable increases in shares of Nanjing Port, Lianyungang, and Ningbo Maritime [3] - Beauty and personal care stocks also performed well, with companies like Jieya Co. and Furuida reaching their daily limit up [3] - Synthetic biology stocks were active, with companies such as Chuaning Biological, Jindawei, and Hainan Haiya hitting their daily limit up [3] Sector Trends - The synthetic biology sector is expected to grow, with significant applications in various fields, although it currently holds a limited share in the overall chemical market [4] - The international landscape for synthetic biology is primarily dominated by the U.S. and Europe, which may influence domestic policy and development [4] Company Profiles 1. **Chuaning Biological**: Focuses on synthetic biology with products in production and plans to expand into high-value products and efficient strains by 2025 [7] 2. **Jieya Co.**: A leading manufacturer of wet wipes, shifting focus towards wet toilet paper and expanding into medical devices and cosmetics [8] 3. **Furuida**: Aims to build a comprehensive health industry chain, leveraging R&D strengths in cosmetics and pharmaceuticals [8] 4. **Jindawei**: Positioned as a leader in the health supplement market, benefiting from market expansion and stable financial performance [8]

Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

证券代码：002626 证券简称：金达威 公告编号：2025-039 厦门金达威集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦 门金达威投资有限公司（以下简称金达威投资）将其所持有的本公司部分股票 解除质押的通知，现将有关事项公告如下： 一、 股东股份解除质押的基本情况 1. 本次解除质押基本情况 | | 是否为 控股股 东或第 | 本次解除 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 一大股 | 质押股份 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | 称 | 东及其 | 数量 | 比例 | 比例 | | | | | | 一致行 | （股） | | | | | | | | 动人 | | | | | | | | | | | | | | | 广发证 | | 金达威 | 是 | 16,143,850 | 7.63% ...

证券代码：002626 证券简称：金达威 公告编号：2025- 037 二、控股股东股份质押情况 厦门金达威集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦门 金达威投资有限公司（以下简称金达威投资）将其所持有的公司部分股票进行股 票质押的通知，现将有关事项公告如下： 一、 股东进行股票质押的基本情况 是否为控 | | | | 占其 | 占公 | | 是否 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股东或 | | | | 是否 | | | | | | | | | 股东 | | 本次质押 | 所持 | | 司总 | | 为补 | 质押起始 | | | 质押到 | | | 质权 | 质押 | | | | | | | | | | | | | | 第一大股 | | | | 为限 | | | | | | | | | 名称 | | 数量 ...

证券代码：002626 证券简称：金达威 公告编号：2025-038 发明名称：一种沸石珍珠岩粉凝胶壳聚糖树脂吸附剂及其制备方法和透明 质酸的纯化和生产方法 专利号：ZL 2021 1 1633242.0 专利申请日：2021 年 12 月 29 日 专利权人：内蒙古金达威药业有限公司 厦门金达威集团股份有限公司 金达威生物技术（江苏）有限公司 专利权期限：二十年 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司内蒙古金达威 药业有限公司、金达威生物技术（江苏）有限公司，近日收到国家知识产权局颁 发的 1 件发明专利证书，具体情况如下： 证书号：第 7930280 号 授权公告日：2025 年 05 月 09 日 本发明属于微生物提炼技术领域，涉及一种沸石珍珠岩粉凝胶壳聚糖树脂吸 附剂及其制备方法和透明质酸的纯化和生产方法。上述方法具有操作简便、安全、 低污染、低成本、杂质去除率高的优势。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技 ...